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were women. The control group was selected to show an optimal comparability in 
terms of demographic and morbidity measures between the two groups. The inter-
vention group showed better compliance (87.9% vs. 71.4%, p= 0.001). BP control was 
52.5 vs. 53.1% (p= NS) initially and 63.2% vs. 55.6% at the end of the study (p< 0.001) 
for the intervention group vs. control, respectively. The follow-up average cost per 
patient and year was € 377.9 vs. € 442.4, p< 0.001 (reduction in intervention group: 
66 € ). 82% of health care professionals and 91% of patients were satisfied with 
the DMP. ConClusions: The DMP has improved adherence to treatment and BP 
control and has reduced health care management costs. If the study results were 
extrapolated to the overall population of Badalona, a potential saving of 1.7 million 
per year would be achieved.
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objeCtives: Venous thromboembolism (VTE) is a common cardiovascular condition, 
frequently leading to severe complications and requiring high-cost health care interven-
tions. New oral anticoagulants (nOACs) have demonstrated to be efficacious and safe 
in VTE prevention of patients undergoing total hip replacement (THR) and total knee 
replacement (TKR). This analysis is aimed present article aims to evaluate its economic 
impact in the perspective of the Italian SSN. Methods: We conducted a budget impact 
analysis to estimate clinical outcomes and economic consequences associated to the 
reimbursement of apixaban in the prevention of VTE as a consequence of major ortho-
pedic surgery, over a three-year time horizon. The analysis compared two alternative sce-
narios, with apixaban either reimbursed (Scenario B) or not reimbursed (Scenario A) by 
the Italian SSN. Only direct health care costs have been considered. Results: According 
to market assumptions, it is estimated that 1.2%, 3.7%, and 6.5% of THR patients, and 
1.2%, 3.8% and 6.7% of TKR patients, would be treated with apixaban over the first three 
years since launch. The introduction of apixaban, at the estimated daily cost of € 2.48/
die, would translate into a budget impact of € 14.3 mln, € 45.5 mln, and € 81.4 mln at years 
1, 2 and 3 since launch, respectively. This expenditure would be more than offset by sav-
ings, due to: i) reduction of prescriptions of alternative treatment options (other nOACs, 
low-molecular weight heparins, fondaparinux); ii) reduction of the economic burden 
attributable of CV complications of VTE. Finally, Scenario B resulted slightly favourable 
compared to Scenario A, leading to economic savings for about € 50 thousands over 
three years. ConClusions: Reimbursement of apixaban does not determine a budget 
impact increase for Italian SSN, and offers an additional option to prevent high-cost 
event provoked by VTE. Its usage may be considered fully sustainable from a pharmaco-
economic viewpoint.
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Underhill S.M.1, Branscombe N.2, Jofre-Bonet M.3
1Servier Laboratories Ltd., Slough, UK, 2Les Laboratoires Servier, Suresnes, France, 3City 
University London, London, UK
objeCtives: Heart failure places a significant burden on the resources of the NHS. 
The aim of this study was to compare from a budgetary perspective the current treat-
ment of patients with heart failure and left ventricular dysfunction with an estimate 
of what could be achieved if the use of evidence-based medicine was optimised in 
accordance with national guidance. Methods: Quality and Outcomes Framework 
prevalence and Hospital Episode Statistics data 2011/12 were analysed to determine 
the number of hospital admissions associated with patients with a diagnosis of heart 
failure for each Clinical Commissioning Group (CCG) and GP Practice in England. These 
data were adjusted for patients with left ventricular dysfunction who were in sinus 
rhythm and hospitalisation costs were applied. This was combined with the cost 
associated with the current use of evidence-based medicine to determine the total 
cost associated with this condition. This was compared with an estimate of total costs 
(hospitalisation and medication) if patients received the levels of evidence-based 
therapy, and outcomes, reported in the SHIFT trial. SHIFT was chosen as the largest 
and most recent contemporary trial in heart failure and left ventricular dysfunction, 
which reflects the optimal use of recommended therapies. Data for each CCG and 
GP practice in England is available via a model presented in Microsoft excel® or 
Apple numbers®. Results: Increasing the use of evidence-based therapy to the 
levels achieved in the SHIFT trial can potentially release estimated funding of up to 
£175m for the population of England, £810,000 for a CCG with a population of 250,000 
and £32,000 for a GP practice with a list size of 10,000. ConClusions: If the use of 
evidence-based therapy for patient’s heart failure and left-ventricular dysfunction is 
increased from current levels, significant improvements in terms of patient outcomes 
and the use of NHS funding can be achieved.
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objeCtives: Drug Eluting Balloon (DEB) is a promising alternative for the treat-
ment of patients with peripheral arterial disease, due to the potential reduction 
in re-intervention rates and cost-savings compared to other technologies com-
monly used. The objective of this analysis was to assess the economic impact of 
DEB and other endovascular therapies for patients with femoral-popliteal dis-
ease. Methods: A budget impact model was developed to compare the relative 
impact in Italy of four different index procedure treatments (PTA with regular bal-
loons, DEB, bare metal stents (BMS) and drug eluting stents (DES)) based on the 
PCV34
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dIsease: Cross-seCtIonal study wIth PaIred grouPs from eleCtronIC 
PatIent reCords
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objeCtives: Electronic Patient Record has proven useful to assess the benefits, 
harms and costs in the real world. To describe the association between the use 
of statins and cardiovascular events in patients with myocardial ischemia by 
means an Electronic Patient Record (ePR) as the basis for a retrospective cohort 
study. Methods: To evaluate the association between the use of statins and car-
diovascular events, we conducted a cross-sectional study with patients in the ePR 
of the Heart Institute (InCor) - University of São Paulo Medical School. Patients were 
considered for the period between 2004 and 2012 and evaluated in terms of the 
association between the use of statins with prevalence of percutaneous coronary 
intervention (PCI), coronary artery bypass graft (CABG) and inpatient mortality. A 
total of 46,757 patients were randomly selected and matched for gender, age group 
(18-49/50-59/60-69/> 70), and category of cardiovascular disease diagnosis, being 
from three ICD-10 groupings, I20-I25/I63-I69/G45/I70. The pairing resulted in two 
groups, each of them with 14,654 patients, a group with prescription of statin (SG) 
and a group for comparison (CG) without statin. Results: A total of 67.4% of the 
patients registered in the ePR used statins. The presence of reverse causality, very 
common in cross-sectional studies, was observed in patients submitted to revascu-
larization procedures. Revascularization was made present in 14% of CG versus 42% 
of SG, which is justified by the drug administration for care of patients undergoing 
those procedures. Mortality was 5.8% in CG and 4.7% in SG, with prevalence rates 
of 80%. The absolute reduction in the prevalence of death between groups was 
1.1% (95%CI:0,6-1,6%) in favor of the use of statins. ConClusions: Statins were not 
prescribed to approximately one third of the patients, the use of statins was higher 
in patients undergoing revascularization procedures and, was also associated with 
a 20% reduction in the occurrence of mortality.
CardIoVasCular dIsorders – Cost studies
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objeCtives: The SSI rate after cardiothoracic surgery is estimated at 7.3% by the 
UK Health Protection Agency (HPA) for high risk patients. This represents a burden 
on resources, through greater risk of in-hospital mortality and increased length 
of hospital stay (mean 22.1 extra days for deep SSI). Treatment guidelines recom-
mend IV antibiotic prophylaxis before surgery; however a challenge in high-BMI 
and diabetic patients (high risk) is the inability of systemic antibiotics to suffi-
ciently penetrate target tissue. It is however estimated that 40%-60% of SSIs are 
avoidable, with clinical data supporting additional use of local gentamicin-collagen 
for SSI prevention. The purpose of this study was to examine the budget impact 
case from a UK NHS perspective of routinely administering gentamicin-collagen 
local prophylaxis against SSI in high risk patients undergoing cardiothoracic sur-
gery. Methods: A literature review was undertaken regarding gentamicin-collagen 
efficacy in reducing SSI in cardiothoracic patients, NHS costs of SSI, and annual UK 
cardiothoracic patient numbers. The SSI rate in cardiothoracic surgery was obtained 
from HPA data. Findings were incorporated into a decision tree budget impact model 
to analyse potential savings from routine use of gentamicin-collagen in high risk 
cardiothoracic patients. Results: Considering a cohort of 3710 high-risk cardio-
thoracic patients, annual NHS costs of SSI are £2,164,316. Administration of two 
gentamicin-collagen implants to each high risk patient would cost £200 per patient. 
Assuming a 59% reduction in SSI; this would prevent 197 sternal wound infections, 
with direct savings of £1,590,882 per year, a net saving of £229 per cardiothoracic 
surgery patient. ConClusions: Significant NHS and hospital trust savings may 
be achievable through routine use of gentamicin-collagen implants in high risk 
cardiothoracic surgery patients. A conservative estimate of high-risk patient num-
bers was used in the analysis, suggesting the scope for budgetary savings could 
exceed reported findings.
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adherenCe In the seCond year of Its ImPlementatIon (2011-2012)
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objeCtives: To evaluate effectiveness of an interventional strategy (disease man-
agement program (DMP)) supported by a telemedicine platform in patients with 
mild/moderate hypertension. Methods: Quasi-experimental design, paired data 
with control group (1:2, patients were matched by age and gender). Study pop-
ulation and follow-up period: patients from 6 primary care centers in Badalona 
(Barcelona, Spain) were followed-up during 2011 and 2012. Study groups: interven-
tion group (telemedicine program) and control group (usual clinical practice). The 
intervention consisted on establishing a permanent channel of interaction with 
the patient (telemedicine platform) and providing the patient with educational 
materials, clinical monitoring, SMS, phone calls, etc. Main measures: Demographic, 
co-morbidity, anthropometric and biochemical parameters, adherence to treat-
ment, blood pressure control (BP: 140/90 mmHg), associated health care man-
agement costs and satisfaction surveys to professionals and patients. Statistical 
significance:p< 0.05. Results: A total of 750 patients were included (intervention 
group n= 250, control group n= 500). Mean age was of 64.2 years old 52.1% of patients 
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for treatment with dabigatran. It is assumed that all diagnosed AF patients eligible 
for oral anticoagulation currently receive warfarin and that all patients switch to 
dabigatran in Year 1, regardless of International Normalised Ratio (INR) control 
amongst warfarin patients. Differences in numbers of clinical events expected to 
occur based on a patient’s antithrombotic treatment were estimated by applying 
event rates from literature sources. Costs were estimated from a HSE perspective and 
included costs of clinical events, disability costs and medication costs. Results: 
A total of 28,332 Irish patients are estimated to have been diagnosed with AF and 
are eligible for dabigatran. Switching these patients from warfarin to dabigatran 
may avoid: 657 strokes; 792 major bleeds; 1,437 deaths. By Year 5, cumulative dabi-
gatran drug costs were estimated at € 7,670,870. Cost savings due to clinical events 
avoided amounted to € 2,894,743 and savings on disability costs at € 5,563,349, giving 
a total cost saving with dabigatran of € 787,223. ConClusions: Use of dabigatran 
as compared to warfarin for stroke prevention in AF in the Irish setting may avoid 
a significant number of clinical events and result in overall cost savings.
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eConomIC Burden of Venous thromBoemoBlIsm aCross PatIent 
PoPulatIons: a lIterature reVIew
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objeCtives: To conduct a literature review on the economic burden of venous throm-
boembolism (VTE) (encompassing deep vein thrombosis (DVT) and pulmonary embo-
lism (PE)) and related complications. Methods: Eligible English-language studies 
published post-1990 were identified from electronic databases (Medline, EMBASE 
and Cochrane Library: accessed December 2012) and conference proceedings with 
no restriction on geographical location or patient population. All costs are reported 
in US$ adjusted to 2013 levels. Results: Twenty-nine studies met eligibility criteria: 
United States (n= 17), Canada (n= 2), Australia (n= 1), South America (n= 1) and Europe 
(n= 8). The estimated annual cost of VTE treatment is in excess of $2 billion in the 
USA and Europe and $153 million in Australia. This figure rises to $15.6–$34.8 billion 
in the US and to $1.78 billion in Australia on inclusion of complications, productivity 
loss and other societal costs. The cost of treating PE per patient ($12,567-$20,488) is 
higher than that of treating DVT ($2,912-$13,299). Hospitalisation is the main cost 
driver for VTE treatment, accounting for 56%-89% of all treatment costs. For patients 
with cancer, costs were 30-50% higher for those with VTE compared with those with-
out VTE. VTE-related complications incur additional costs including: bleeding (up to 
$23,963 per patient with a major bleed); recurrent VTE (up to $18,122 per patient); 
post-thrombotic syndrome (increase of up to 75% in treatment cost); chronic throm-
boembolic pulmonary hypertension (up to $6,708 per patient); and heparin-induced 
thrombocytopenia (up to $18,779 per patient). ConClusions: Incident VTE events 
and related complications are associated with significant economic burden across 
several patient populations. Treating PE may cost up to five times more than treating 
DVT, with hospitalisation reported as the major cost driver of VTE treatment. Effective 
and convenient therapies associated with both a reduced incidence of bleeding and 
complications are required to further reduce the cost burden associated with VTE.
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PharmaCoeConomIC asPeCts of aCtoVegIn and solCoseryl In the 
treatment of russIan PatIents wIth aCute CereBroVasCular 
aCCIdents
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objeCtives: To assess the cost-effectiveness of actovegin and solcoseryl in the treat-
ment of Russian patients with acute ischemic stroke and predict potential budget 
impact of the implementation of actovegin in routine clinical practice. Methods: 
The pharmacoeconomic model was developed based on the data from Russian 
clinical trial performed by A. Fedin et al. (2000). Two groups of patients (100 persons 
each) hospitalized with acute ischemic stroke were included in the model. The first 
group of patients received conventional therapy + actovegin and the second group 
received conventional therapy + solcoseryl. Based on the reported by A. Fedin et al. 
time-dependent mortality reduction in actovegin-treated patients (mortality rate 
was 7% in patients started actovegin within the first 6 hours after stroke onset, 
10% – in those started actovegin within the first 24 hours, 14% – in those started 
actovegin after more than 24 hours, and it was much higher in the control group – 
21%) cost-effectiveness ratios (CERs) and indicator of economic rationality of costs 
of previous periods (IRPP) were calculated and compared. Results: Estimated CERs 
varied from 46,348.82 to 50,121.40 RUB per one survivor in the actovegin group and 
from 50,900.56 to 53,585.17 RUB per one survivor in the solcoseryl group. Inefficient 
expenditures (IRPP) varied from 301,730.83 RUB to 603,461.67 RUB in the actovegin 
group, and were 873,453.57 RUB in the solcoseryl group. ConClusions: The study 
has demonstrated the preferred cost-effectiveness profile of actovegin as compared 
to solcoseryl in patients with acute ischemic stroke.
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objeCtives: To assess the cost-effectiveness of citicoline in the treatment of Russian 
patients with acute ischemic stroke and identify potential budget impact of the imple-
mentation of citicoline in routine clinical practice. Methods: The pharmacoeco-
nomic model was developed based on the data of meta-analysis performed by A. 
Davalos et al. (2002). Two groups of 100 patients each were included in the model: the 
first group of patients received conventional therapy and the second group (active 
treatment group) additionally received citicoline. It was assumed that citicoline was 
given to patients in the active treatment group in the following way: during the first 
repeat procedure rates (TLR - target lesion revascularization) over 1 year. The model 
was developed from a Italian national health care system (NHS) perspective with 
a 5-year time horizon. A systematic literature review was carried out on TLR rates 
in patients with femoral-popliteal disease treated with one of the four treatment 
choices. Costs associated to each treatment are derived from the average DRG tariffs 
used for peripheral angioplasty procedures. A decision analytic model was devel-
oped to estimate total costs over 12 months of index procedures and possible revas-
cularizations. Results: Pooled 12-month TLR rates show clear patients benefit with 
DEB compared to PTA (8,6% vs 28,6%) and non-inferiority of DEB vs DES (9,4%) and 
BMS (11,5%). Total Italian DRG payments for index and repeat interventions (based 
on TLR rates estimation) across treatments showed that DEB was the least costly 
treatment strategy over 1 year, with saving of almost € 1,000 per patient with DEB 
vs PTA. Based on these per-patient savings, the potential total savings amounted 
to approximately € 2 million for an assumed annual increase of 5% in DEB adoption 
rate over 5 years. ConClusions: The analysis suggests clear patient benefit for 
DEB. Despite initial higher investments, DEB represents a cost-saving alternative 
to other technologies according to the NHS perspective.
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objeCtives: In Italy about 500,000 non-valvular atrial fibrillation (NVAF) patients 
have a major unmet medical need as they do not receive adequate anticoagulation 
therapy for stroke prophylaxis: many patients receive antiplatelet therapy, even 
when the guidelines recommend vitamin-K antagonists (VKA), or are not treated at 
all or have international normalized ratio inadequate control despite treatment with 
VKA. The purpose of this study was to perform a budget impact analysis of rivaroxa-
ban - a novel oral anticoagulant (NOAC) - in NVAF patients with the highest unmet 
medical need from the Italian health care system (SSN) perspective. Methods: 
Two scenarios were compared within a three-year timeframe: the actual scenario, 
where patients are treated according to current clinical practice (46% with VKA, 
38% with antiplatelets, 17% non-treated) and a scenario where Rivaroxaban is pre-
sent with increasing market shares. The event risks (ischemic and haemorrhagic 
stroke, systemic embolism, myocardial infarction and bleedings) were retrieved 
from the ROCKET-AF trial or from a network meta-analysis. Resource consumption 
was computed using mean regional tariffs. Since Rivaroxaban price is not officially 
published, the daily cost used ranges from € 2.10 (price of the first NOAC approved in 
this indication in Italy) and the lowest Rivaroxaban price available in Europe (€ 1.94). 
The results of the analysis are displayed as a total costs difference between the two 
scenarios. Results: A reduction in the total number of events and costs at SSN 
charge is shown since the first year from rivaroxaban introduction. The increase in 
pharmaceutical expenditure is offset by savings from a lower number of events to 
treat and absence of routine coagulation monitoring. ConClusions: The introduc-
tion of rivaroxaban in the national scenario is beneficial because it will provide a 
substantial reduction in the disease burden for patients and in costs for the SSN.
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ComParIson of daBIgatran etexIlate Versus warfarIn, asPrIn & no 
treatment for stroke PreVentIon In atrIal fIBrIllatIon In england, 
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objeCtives: To estimate the number of clinical events and costs of these events 
for dabigatran etexilate (dabigatran) versus a combination of warfarin, aspirin and 
no treatment for stroke prevention in atrial fibrillation (AF) patients in an England, 
UK, setting over 5 years. Methods: An interactive model was built in Microsoft 
Excel to calculate the following: • Total number of AF patients eligible for dabi-
gatran • Number of clinical events for dabigatran, warfarin, aspirin and no treat-
ment patients over a 5 year time horizon. Clinical events included were stroke 
(ischaemic, haemorrhagic, systemic embolism); major bleeding (intracranial and 
extracranial); all cause mortality; acute myocardial infarction • Total costs of clini-
cal events for each treatment. The total cost per day for dabigatran is £2.20 per day; 
warfarin is £1.18; aspirin is £0.09; no treatment is £0.00. Warfarin had a TTR of 55% 
(from Jones et al 2005); aspirin and no treatment clinical event rates were from 
Roskell et al (2010). Dabigatran data was from the RE-LY trial Results: The model 
estimates there are 822,527 patients with AF in England, of which 78% are eligible 
for dabigatran (641,571). After 5 years, patients treated with dabigatran versus 80% 
with warfarin; 10% aspirin; 10% no treatment are associated with: 1) 27,357 fewer 
strokes (16,938 fewer ischaemic storkes); 2) 14,413 fewer major bleeding events; 
and 3) An increase of £268,167,861 in drug budget; however there is an overall cost 
saving of £11,240,201. The overall cost saving is predominantly driven by savings in 
disability following stroke. ConClusions: Study indicates that due to a superior 
clinical profile, dabigatran may more than offset the increase drug budgets, result-
ing in cost savings, if used preferentially versus warfarin, aspirin or no treatment.
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objeCtives: To estimate numbers of clinical events (strokes, major bleeds, acute 
myocardial infarctions and deaths) and health care costs over a five year period 
in Ireland following a switch of antithrombotic therapy for atrial fibrillation (AF) 
from warfarin to dabigatran. Methods: A model was built in Microsoft Excel and 
included an estimate of the number of Irish patients diagnosed with AF and eligible 
